Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase 2 Completed
176 enrolled 18 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Completed
30 enrolled
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
Phase 2 Completed
21 enrolled 5 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase 2 Terminated
3 enrolled 6 charts
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Phase 2 Withdrawn
FM 140 vs FM100 Study in Patients With Multiple Myeloma
Phase 2 Completed
52 enrolled 7 charts
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
Cellular Therapy With Cord Blood Cells
Phase 2 Completed
31 enrolled 6 charts